Dafna Capital Management LLC
Dafna Capital Management LLC reported 88 US-listed holdings worth $524.4 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Revolution Medicines, Inc. (20.1%), SPDR Ser Trust (5.9%) and Compass Pathways PLC (5.4%). Against the quarter before, it opened 17 positions, added to 17, trimmed 26 and sold out of 11.
Reported holdings$524.4M+20.9% on Q1 2026
Positions88+6 on Q1 2026
The largest ten56.2%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
OpenedAdded toHeldTrimmed
The 14 largest of its 88 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +71.3% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Its reported holdingsThe S&P 500
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Opened 17Added 17Held 28Trimmed 26Sold out 11
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 17
- Ascendis Pharma A/s ASND$12.9 million
- Kymera Therapeutics Inc. KYMR$3.1 million
- Adlai Nortye Ltd ANL$2.8 million
- Nervgen Pharma Corp. NGEN$2.2 million
- Atrium Therapeutics Inc. RNA$1.7 million
- Eupraxia Pharmaceuticals Inc. EPRX$1.5 million
- Design Therapeutics Inc. DSGN$1.5 million
- Corbus Pharmaceuticals Hldgs CRBP$1.0 million
and 9 more in the table below
Added to 17
- Denali Therapeutics Inc. DNLI+420,514 shares · +132%
- Nektar Therapeutics NKTR+153,202 shares · +93%
- Insulet Corp. PODD+51,000 shares · +469%
- Edgewise Therapeutics Inc. EWTX+114,583 shares · +102%
- Syndax Pharmaceuticals Inc. SNDX+117,900 shares · +54%
- Orthopediatrics Corp. KIDS+93,471 shares · +98%
- Allogene Therapeutics Inc. ALLO+629,882 shares · +46%
- Aquestive Therapeutics Inc. AQST+277,500 shares · +75%
and 9 more in the table below
Trimmed 26
- SPDR Ser Trust XBI-122,000 shares · -38%
- Biohaven Ltd BHVN-708,142 shares · -84%
- MBX Biosciences Inc. MBX-163,656 shares · -93%
- Compass Pathways PLC CMPS-406,930 shares · -17%
- Bicara Therapeutics Inc. BCAX-136,778 shares · -32%
- Cytokinetics Inc. CYTK-45,499 shares · -21%
- iShares Trust IBB-19,500 shares · -31%
- Revolution Medicines, Inc. RVMD-18,048 shares · -3%
and 18 more in the table below
Sold out of 11
- Day One Biopharmaceuticals I DAWN$21.0 million last quarter
- Kalvista Pharmaceuticals Inc. KALV$5.4 million last quarter
- Ascendis Pharma A/s ASND$5.3 million last quarter
- Fulcrum Therapeutics Inc. FULC$1.6 million last quarter
- Engene Holdings Inc. ENGN$1.3 million last quarter
- Scynexis Inc. SCYX$996,630 last quarter
- Oric Pharmaceuticals Inc. ORIC$945,460 last quarter
- Zenas Biopharma Inc. ZBIO$830,875 last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Revolution Medicines, Inc. RVMD | 562.6K | $105.4 million | 20.09% | -18.0K |
| SPDR Ser Trust XBI | 196.5K | $31.1 million | 5.93% | -122.0K |
| Compass Pathways PLC CMPS | 2.0M | $28.5 million | 5.43% | -406.9K |
| Stereotaxis Inc. STXS | 13.7M | $23.5 million | 4.49% | no change |
| Nektar Therapeutics NKTR | 318.4K | $22.2 million | 4.24% | +153.2K |
| Denali Therapeutics Inc. DNLI | 739.0K | $19.0 million | 3.62% | +420.5K |
| Ideaya Biosciences Inc. IDYA | 497.2K | $18.5 million | 3.53% | +20.5K |
| Atricure Inc. ATRC | 597.4K | $16.7 million | 3.19% | no change |
| Xenon Pharmaceuticals Inc. XENE | 250.8K | $15.1 million | 2.89% | no change |
| Cytokinetics Inc. CYTK | 172.0K | $14.7 million | 2.79% | -45.5K |
| Arcus Biosciences, Inc. RCUS | 441.8K | $13.6 million | 2.60% | -2.0K |
| Ascendis Pharma A/s ASND | 48.5K | $12.9 million | 2.47% | new |
| Neurocrine Biosciences Inc. NBIX | 57.8K | $9.7 million | 1.86% | -12.8K |
| Axogen Inc. AXGN | 209.0K | $9.7 million | 1.84% | -41.0K |
| Insulet Corp. PODD | 61.9K | $9.4 million | 1.80% | +51.0K |
| Edgewise Therapeutics Inc. EWTX | 226.8K | $9.2 million | 1.76% | +114.6K |
| Bicara Therapeutics Inc. BCAX | 285.0K | $8.5 million | 1.61% | -136.8K |
| iShares Trust IBB | 42.6K | $8.1 million | 1.54% | -19.5K |
| Syndax Pharmaceuticals Inc. SNDX | 335.3K | $7.3 million | 1.40% | +117.9K |
| Maplight Therapeutics Inc. MPLT | 171.0K | $6.1 million | 1.17% | no change |
| Larimar Therapeutics Inc. LRMR | 2.0M | $6.1 million | 1.17% | -21.0K |
| Century Therapeutics Inc. IPSC | 2.4M | $5.9 million | 1.12% | -33.9K |
| Dexcom Inc. DXCM | 86.3K | $5.8 million | 1.11% | no change |
| Immunovant Inc. IMVT | 149.5K | $5.8 million | 1.10% | -1.0K |
| Inogen Inc. INGN | 845.2K | $5.5 million | 1.04% | no change |
| Tandem Diabetes Care Inc. TNDM | 355.2K | $5.4 million | 1.02% | no change |
| Alkermes plc. ALKS | 101.3K | $5.3 million | 1.01% | -38.2K |
| Stoke Therapeutics Inc. STOK | 130.9K | $4.3 million | 0.82% | no change |
| Allogene Therapeutics Inc. ALLO | 2.0M | $4.2 million | 0.79% | +629.9K |
| Biocryst Pharmaceuticals Inc. BCRX | 400.2K | $4.0 million | 0.76% | -30.0K |
| Galapagos NV LKFT | 130.2K | $3.9 million | 0.74% | no change |
| Orthopediatrics Corp. KIDS | 189.1K | $3.6 million | 0.69% | +93.5K |
| Cybin Inc. HELP | 514.1K | $3.4 million | 0.65% | +15.7K |
| Rapport Therapeutics Inc. RAPP | 75.0K | $3.1 million | 0.60% | no change |
| Kymera Therapeutics Inc. KYMR | 27.0K | $3.1 million | 0.59% | new |
| Proqr Thrapeutics N V PRQR | 1.5M | $2.8 million | 0.54% | -37.2K |
| Neurogene Inc. NGNE | 89.0K | $2.8 million | 0.53% | +32.4K |
| Adlai Nortye Ltd ANL | 239.6K | $2.8 million | 0.53% | new |
| Procept Biorobotics Corp. PRCT | 120.0K | $2.7 million | 0.52% | no change |
| Aquestive Therapeutics Inc. AQST | 645.9K | $2.7 million | 0.51% | +277.5K |
| Celldex Therapeutics Inc. CLDX | 68.5K | $2.5 million | 0.49% | no change |
| Structure Therapeutics Inc. GPCR | 46.5K | $2.5 million | 0.48% | no change |
| Align Technology Inc. ALGN | 14.0K | $2.4 million | 0.45% | -1.0K |
| Viking Therapeutics Inc. VKTX | 59.5K | $2.3 million | 0.44% | no change |
| Nervgen Pharma Corp. NGEN | 1.1M | $2.2 million | 0.41% | new |
| Biohaven Ltd BHVN | 137.6K | $2.0 million | 0.39% | -708.1K |
| Maze Therapeatics MAZE | 65.0K | $1.9 million | 0.37% | +30.0K |
| Alector Inc. ALEC | 908.4K | $1.8 million | 0.35% | no change |
| Lexeo Therapeutics Inc. LXEO | 377.1K | $1.8 million | 0.33% | no change |
| Profound Med Corp. Com New PROF | 260.4K | $1.7 million | 0.33% | -2.6K |
| Atrium Therapeutics Inc. RNA | 128.0K | $1.7 million | 0.33% | new |
| Annexon Inc. ANNX | 297.8K | $1.7 million | 0.32% | +180.0K |
| Cytomx Therapeutics Inc. CTMX | 438.4K | $1.6 million | 0.31% | +208.4K |
| Ultragenyx Pharmaceutical in RARE | 47.1K | $1.6 million | 0.30% | -14.0K |
| Eupraxia Pharmaceuticals Inc. EPRX | 225.6K | $1.5 million | 0.28% | new |
| Design Therapeutics Inc. DSGN | 102.6K | $1.5 million | 0.28% | new |
| Fate Therapeutics Inc. FATE | 525.0K | $1.4 million | 0.27% | -25.0K |
| Mediwound Ltd MDWD | 94.4K | $1.4 million | 0.26% | no change |
| Kura Oncology Inc. KURA | 120.6K | $1.3 million | 0.25% | -115.3K |
| Ars Pharmaceuticals Inc. SPRY | 164.3K | $1.3 million | 0.25% | +25.0K |
| Mineralys Therapeutics Inc. MLYS | 44.5K | $1.2 million | 0.23% | +6.0K |
| Immatics N.V IMTX | 117.0K | $1.2 million | 0.23% | -108.9K |
| Tela Bio Inc. TELA | 1.4M | $1.1 million | 0.21% | no change |
| Polypid Ltd PYPD | 207.9K | $1.1 million | 0.20% | no change |
| Corbus Pharmaceuticals Hldgs CRBP | 107.8K | $1.0 million | 0.19% | new |
| Inspire Medical Systems, Inc. INSP | 18.2K | $811,902 | 0.15% | no change |
| Adicet Bio Inc. ACET | 93.8K | $810,536 | 0.15% | no change |
| Seaport Therapeutics Inc. SPTX | 32.4K | $703,728 | 0.13% | new |
| MBX Biosciences Inc. MBX | 11.8K | $651,857 | 0.12% | -163.7K |
| BioNTech SE BNTX | 7.0K | $651,350 | 0.12% | no change |
| Artiva Biotherapeutics Inc. ARTV | 67.1K | $650,880 | 0.12% | new |
| Pliant Therapeutics Inc. PLRX | 487.0K | $555,180 | 0.11% | no change |
| Scynexis Inc. SCYX | 135.9K | $552,983 | 0.11% | new |
| Editas Medicine, Inc. EDIT | 170.5K | $552,323 | 0.11% | new |
| Orchestra Biomed Holdings in OBIO | 126.8K | $547,319 | 0.10% | no change |
| Foghorn Therapeutics Inc. FHTX | 111.9K | $545,872 | 0.10% | no change |
| Accuray Inc. ARAY | 1.7M | $433,235 | 0.08% | no change |
| Q32 Bio Inc. QTTB | 32.9K | $419,095 | 0.08% | new |
| Nuvectis Pharma Inc. NVCT | 20.0K | $367,800 | 0.07% | new |
| Compugen Ltd CGEN | 168.2K | $360,016 | 0.07% | -89.6K |
| Ibio Inc. Com IBIO | 170.1K | $297,593 | 0.06% | -23.6K |
| Autolus Therapeutics PLC AUTL | 179.3K | $286,906 | 0.05% | no change |
| Bicycle Therapeutics PLC BCYC | 64.5K | $273,446 | 0.05% | no change |
| Tenaya Therapeutics Inc. TNYA | 300.0K | $221,730 | 0.04% | new |
| Verrica Pharmaceuticals Inc. VRCA | 23.8K | $145,350 | 0.03% | -130.0K |
| Engene Therapeut ENGN | 74.7K | $129,145 | 0.02% | new |
| Kardigan Inc. KARD | 5.0K | $119,250 | 0.02% | new |
| Auven Therapeutics Management ADCT | 77.1K | $82,477 | 0.02% | +5.0K |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.